Depending on how ready accountable care organizations (ACOs) are to move to risk probably affects how they view CMS’ decision to transition the Medicare Shared Savings Program (MSSP) to Pathways to Success, said Travis Broome, vice president of policy at Aledade.
Depending on how ready accountable care organizations (ACOs) are to move to risk probably affects how they view CMS’ decision to transition the Medicare Shared Savings Program (MSSP) to Pathways to Success, said Travis Broome, vice president of policy at Aledade.
Transcript
CMS finalized Pathways to Success at the end of 2018; what is the general mood around the latest evolution in MSSP?
Yeah, so the Pathways it basically said we’re going to make the benchmark better, more sustainable for ACOs. I’ve written in AJMC® before about trying to make the MSSP more sustainable over time. So, like, they did that, but they also wanted folks to move to risk a little faster. I think the combination affected ACOs differently.
For us, we’re probably moving to risks faster, because we’ve always intended to go to risk and we have a better benchmark methodology. For other folks who, you know, didn’t want to move to risk or hadn’t already make the decision that risk was in their future, it might have scared them off a little bit.
I think as we get more experience, right, people are literally signing up for the first time, we haven’t had a day of a single ACO in Pathways to Success. So, I think we want people to have experience with it. We’ll see new ACOs joining Pathways to Success when they realize that the finances are a little better and hopefully some of those ACOs that dropped out but really believed in the work and just got a little freaked out by the newness and the changes come back into the program.
A meta-analysis showed that control group outcomes in psilocybin trials for depression were significantly weaker than those in selective serotonin reuptake inhibitor (SSRI) and esketamine trials, suggesting that psilocybin’s large observed treatment effects may be inflated by methodological factors such as functional unblinding and expectancy bias.
Read More
Trump Directs Pharma Companies on Cutting Drug Prices Under Most-Favored-Nation Order
July 31st 2025President Donald Trump has sent letters to pharmaceutical companies, aiming to compel them to lower drug prices in the US to match the lowest prices offered in other developed nations, a move that could significantly reduce costs and disrupt the current system of pharmacy benefit managers.
Read More
Legal Navigation Services Key to Addressing Disparities in Cancer Care
July 31st 2025A significant number of patients with cancer, caregivers, and health care professionals face significant disparities in legal issues, with the most common needs revolving around health insurance, finances, employment, and disability insurance.
Read More